Monitoring may perhaps be a promising biomarker to predict tumour response and the clinical end result.ISEV2019 ABSTRACT BOOKSymposium Session 32: Late Breaking- EV Labeling, Separation, and Detection Chairs: Elisa Lazaro-Ibanez; CD54/ICAM-1 Proteins Biological Activity Ryou-u Takahashi Location: Degree B1, Lecture Room 09:300:LB04.A microfluidic gadget with nanoscale surface topology and functionalized with lipid nanoprobes for extracellular vesicle isolation and clinical cancer diagnosis Yuan Wana, Mackenzie Maurerb, Hong-Zhang Heb, Yi-Qiu Xiab, Wen-Long Zhangb, Si-Jie Haob, Nelson Yeec and Siyang ZhengbbBinghamton University, State CD117/c-KIT Proteins Accession University of Ny, Binghamton, USA; The Pennsylvania State University, University Park, USA; cPenn State College of Medicine, Hershey, USAaSummary/conclusion: This new platform suggests that MAF of EV-derived DNA can have big patient variability that could depend upon cancer form, stage, progression, or other pathophysiological components. These effects assistance the want to get a rapid and trustworthy EV isolation method, this kind of as this reported gadget. Funding: This get the job done was supported from the National Cancer Institute on the US National Institutes of Health and fitness underneath grant amount 1R01CA230339 to S. Y. Zheng.Introduction: Extracellular vesicles (EVs) are cellderived, lipid membrane enclosed particles. Tumour cell-derived are more and more acknowledged for his or her pathophysiological contributions and probable towards cancer diagnosis and treatment method monitoring. On the other hand, clinical translation of EVs is limited by technological issues for EV isolation. A rapid, highthroughput, and on-chip EV isolation technologies is important for EV-based cancer diagnosis. Strategies: We report a lipid nanoprobe-functionalized nanostructured silica microfluidic gadget that will be utilized in combination with nucleic acid extraction, and digital droplet polymerase chain response (ddPCR) for EV isolation, enrichment, and DNA mutation detection from clinical plasma samples for cancer diagnosis. The gadget includes EV-size-matched silica nanostructures, surface-grafted lipid nanoprobes in addition to a polydimethylsiloxane (PDMS) herringbone micromixer chamber. Plasma samples are collected from both cell lines or clinical samples (IRB authorized and sufferers consented). As plasma flows via the microfluidic device, the EVs are isolated. EV DNA is then extracted and pathological mutations are detected with ddPCR. Outcomes: The microfluidic gadget removes 96.five plasma proteins. The restrict of detection of a KRAS mutation from plasma EV by ddPCR is 0.01 mutant allele fraction (MAF). The device is validated inside a pilot clinical examine for pancreatic cancer diagnosis. Clinical samples with identified KRAS mutations in the tissue had been validated together with the device. ddPCR indicated MAF of one.8 , 10.one , and 22.3 , respectively, from DNA extracted from plasma EV, while none have been detected in healthy controls.LB04.Asparagine-linked glycosylation amplifies the heterogeneity of tumour extracellular vesicles Yoichiro Haradaa, Kazuki Nakajimab, Nobuyoshi Kosakac, Tomoko Fukushiged, Kiyotaka Kondoa, Junichi Seinoe, Tadashi Suzukie, Hiromasa Inouea, Takuro Kanekuraf, Takahiro Ochiyac and Ikuro MaruyamaaaKagoshima University Health care and Dental Sciences, Kagoshima, Japan; Fujita Overall health University, Aichi, Japan; cDepartment of Molecular and Cellular Medication, Institute of Healthcare Science, Tokyo Health-related University, Tokyo, Japan; dKagoshima Univeristy Health-related and Dental Sciences, Kagoshima, Japan; eRIKEN, Saitama, JapanbIntroduction: Tumo.